Roche (RHHBY) announced that the European Medicines Agency has approved Vabysmo or faricimab, 6.0 mg single-dose prefilled syringe for use in the treatment of neovascular or 'wet' age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. Vabysmo PFS delivers the same medicine as the currently available 6.0 mg Vabysmo vials in a ready-to-use format. The company noted that Vabysmo PFS provides ophthalmologists with the first and only CE-labelled needle for intravitreal injection.
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said: "This simplified administration may thereby help reduce the treatment burden for patients and retina specialists."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.